Literature DB >> 28120476

Mineral adaptations following kidney transplantation.

Sven-Jean Tan1,2, Amy Crosthwaite2,3, David Langsford4, Varuni Obeysekere5, Frank L Ierino2,6,7, Matthew A Roberts7,8, Peter D Hughes1,2, Tim D Hewitson1,2, Karen M Dwyer2,6,7,9, Nigel D Toussaint1,2.   

Abstract

Klotho is predominantly expressed in the kidney and reported to have antioxidant and antifibrotic properties. Soluble Klotho (sKl), the circulating protein cleaved from membrane-bound Klotho, is reduced significantly with kidney disease and inversely associated with mortality. sKl has not been thoroughly evaluated prospectively after kidney transplantation. Incident kidney transplant recipients (KTRs) were prospectively evaluated pretransplantation, 1, 12 and 52 weeks post-transplantation. Basic biochemistry, sKl and intact FGF23 were measured. Within-subject comparisons were evaluated using repeat-measure anova or Friedman's analysis. Effects of immunosuppression and biochemical parameters on sKl and FGF-23 over time were analysed using mixed-effects modelling. Median serum creatinine (sCr) at 1 week was 116 (92-142) μmol/l, and at 52 weeks, all 29 KTRs had a functioning graft with median sCr of 111 (97-131) μmol/l. Compared with baseline, sKl was increased at 52 weeks following an initial decline at 1 week (P < 0.005 and P < 0.01, respectively), while FGF23 was considerably reduced at 52 weeks (P < 0.001). In a mixed-effects model, an increased sKl was not associated with reduction in immunosuppression or evaluated biochemical parameters. Modest increase in sKl is observed one-year postkidney transplantation with excellent early graft function suggesting factors beyond renal capacity may influence circulating sKl. FGF23 normalization was observed. Longer term evaluation in transplantation, specifically addressing the effects of immunosuppression, is required to understand the pathophysiology of the sKl/FGF23 axis and potential for modification.
© 2017 Steunstichting ESOT.

Entities:  

Keywords:  fibroblast growth factor-23; kidney transplant recipient; phosphate; soluble Klotho

Mesh:

Substances:

Year:  2017        PMID: 28120476     DOI: 10.1111/tri.12925

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

Review 1.  αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight.

Authors:  Edward R Smith; Stephen G Holt; Tim D Hewitson
Journal:  Cell Mol Life Sci       Date:  2019-07-26       Impact factor: 9.261

Review 2.  The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation.

Authors:  Meera Gupta; Gabriel Orozco; Madhumati Rao; Roberto Gedaly; Hartmut H Malluche; Javier A Neyra
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 3.  α-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent.

Authors:  Reinhold G Erben
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-07       Impact factor: 2.894

4.  Serum Klotho in Living Kidney Donors and Kidney Transplant Recipients: A Meta-Analysis.

Authors:  Charat Thongprayoon; Javier A Neyra; Panupong Hansrivijit; Juan Medaura; Napat Leeaphorn; Paul W Davis; Wisit Kaewput; Tarun Bathini; Sohail Abdul Salim; Api Chewcharat; Narothama Reddy Aeddula; Saraschandra Vallabhajosyula; Michael A Mao; Wisit Cheungpasitporn
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

5.  Cholecalciferol supplementation effectively improved tertiary hyperparathyroidism, FGF23 resistance and lowered coronary calcification score: a prospective study.

Authors:  Shu-Meng Hu; Yang-Juan Bai; Ya-Mei Li; Ye Tao; Xian-Ding Wang; Tao Lin; Lan-Lan Wang; Yun-Ying Shi
Journal:  Endocr Connect       Date:  2022-07-25       Impact factor: 3.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.